thiophenes has been researched along with osteoprotegerin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Geusens, P; Reid, D | 1 |
| Atkins, GJ; Findlay, DM; Halbout, P; Welldon, KJ | 1 |
| Masuda, H; Tanaka, S | 1 |
| Atwa, S; Brennan, TC; Conigrave, AD; Green, W; Mason, RS; Rybchyn, MS | 1 |
| Goëb, V; Trouvin, AP | 1 |
| Brzeziańska, E; Cegłowska, A; Liberski, PP; Rieske, P; Sewerynek, E; Stêpień-Kłos, W; Stuss, M | 1 |
| Cui, J; Geng, D; Liu, X; Shao, H; Xu, Y; Yang, H; Yu, L; Zhang, W; Zhu, S | 1 |
| Khlusov, IA; Nechaev, KA; Vengerovskiĭ, AI | 1 |
| Jędrzejczyk, S; Król, I; Sewerynek, E; Stępień-Kłos, W; Stuss, M | 1 |
| Akpınar, A; Göze, F; Karakan, NC; Poyraz, Ö | 1 |
| Chen, X; Geng, T; Guo, H; Jin, Q; Sun, S; Wang, B; Zhang, S | 1 |
| Chen, X; Geng, T; Guo, H; Jin, Q; Sun, S; Yu, H; Zhang, S; Zheng, M | 1 |
| da Silva, HDP; Duarte, PM; Franco, BDST; Malta, FS; Marins, LM; Miranda, TS; Nani, EP; Napimoga, MH | 1 |
5 review(s) available for thiophenes and osteoprotegerin
| Article | Year |
|---|---|
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Newer drug treatments: their effects on fracture prevention.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid | 2005 |
[Drugs under development for osteoporosis ].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cathepsin K; Cathepsins; Denosumab; Diphosphonates; Drug Design; Humans; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes | 2009 |
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
Topics: Aging; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Female; Humans; Male; Mice; NF-kappa B; Organometallic Compounds; Osteoblasts; Osteoclasts; Osteoporosis; Osteoprotegerin; RANK Ligand; Rats; Thiophenes | 2010 |
[Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Topics: Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Gene Expression Regulation; Geranyltranstransferase; Humans; Osteoblasts; Osteoclasts; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Thiophenes; Wnt Proteins | 2014 |
1 trial(s) available for thiophenes and osteoprotegerin
| Article | Year |
|---|---|
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Gene Expression Regulation; Humans; Ibandronic Acid; Leukocytes, Mononuclear; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; RNA, Messenger; Thiophenes | 2013 |
8 other study(ies) available for thiophenes and osteoprotegerin
| Article | Year |
|---|---|
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response.
Topics: Apoptosis; Bone Density Conservation Agents; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Organometallic Compounds; Osteoblasts; Osteocytes; Osteoprotegerin; Phenotype; Thiophenes | 2009 |
Osteoblasts play key roles in the mechanisms of action of strontium ranelate.
Topics: Anabolic Agents; Bone Density Conservation Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Gene Knockdown Techniques; Humans; Organometallic Compounds; Osteoblasts; Osteoclasts; Osteoprotegerin; RANK Ligand; Receptors, Calcium-Sensing; RNA, Messenger; RNA, Small Interfering; Thiophenes | 2009 |
Strontium ranelate inhibits titanium-particle-induced osteolysis by restraining inflammatory osteoclastogenesis in vivo.
Topics: Acid Phosphatase; Animals; Inflammation; Interleukin-1beta; Isoenzymes; Male; Mice, Inbred C57BL; Osteoclasts; Osteogenesis; Osteolysis; Osteoprotegerin; RANK Ligand; RNA, Messenger; Skull; Staining and Labeling; Tartrate-Resistant Acid Phosphatase; Thiophenes; Titanium; Tumor Necrosis Factor-alpha; X-Ray Microtomography | 2014 |
Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Thiophenes | 2016 |
Investigating the Effects of Systemically Administered Strontium Ranelate on Alveolar Bone Loss Histomorphometrically and Histopathologically on Experimental Periodontitis in Rats.
Topics: Alkaline Phosphatase; Alveolar Bone Loss; Animals; Biomarkers; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Interleukin-1beta; Male; Osteoclasts; Osteoprotegerin; Periodontitis; Random Allocation; RANK Ligand; Rats; Rats, Wistar; Thiophenes | 2017 |
Strontium ranelate reduces the progression of titanium particle-induced osteolysis by increasing the ratio of osteoprotegerin to receptor activator of nuclear factor-κB ligand in vivo.
Topics: Administration, Oral; Alloys; Animals; Biomarkers; Bone Density Conservation Agents; Bone-Implant Interface; Dose-Response Relationship, Drug; Female; Gene Expression; Mice; Mice, Inbred C57BL; Osteolysis; Osteoprotegerin; Particulate Matter; Prostheses and Implants; Prosthesis Failure; RANK Ligand; Thiophenes; Tibia; Titanium | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Humans; Mice; Osteocalcin; Osteoclasts; Osteogenesis; Osteolysis; Osteoporosis; Osteoprotegerin; Prosthesis Failure; Thiophenes | 2018 |
Effects of strontium ranelate on ligature-induced periodontitis in estrogen-deficient and estrogen-sufficient rats.
Topics: Alveolar Bone Loss; Animals; Estrogens; Osteocalcin; Osteopontin; Osteoprotegerin; Ovariectomy; Periodontitis; RANK Ligand; Rats; Rats, Wistar; Thiophenes | 2020 |